Dermatofibrosarcoma Protuberans Treatment Guidelines

Introduction to DFSP Treatment

The National Comprehensive Cancer Network recommends surgery with complete margin assessment as the definitive treatment for DFSP 6
Imatinib mesylate is the standard medical therapy for dermatofibrosarcoma protuberans (DFSP) when patients are not amenable to surgery or have metastatic disease requiring systemic treatment 1, 2, 3, 4, 5

Imatinib is indicated for unresectable disease where surgery would result in unacceptable functional or cosmetic outcomes, although this specific point is from Praxis Medical Insights, a similar indication can be found in the context of neoadjuvant use to downsize tumors and make them resectable 6
The American College of Surgeons and other organizations imply that imatinib can be used for recurrent disease not amenable to further surgery, in the context of discussing the role of surgery and systemic therapy in DFSP management 6

The standard dose of imatinib is 800 mg daily, administered as 400 mg twice daily, as recommended by various guidelines including those from the National Comprehensive Cancer Network 8, 9, 10

DFSP is characterized by t(17;22) chromosomal translocation in more than 90% of cases, resulting in COL1A1-PDGFβ fusion gene and constitutive activation of platelet-derived growth factor receptor (PDGFR), as noted by the National Comprehensive Cancer Network 6
Molecular analysis using cytogenetics, FISH, or PCR should be performed before initiating therapy to confirm the presence of COL1A1-PDGFβ fusion, as recommended by guidelines from the National Comprehensive Cancer Network and other organizations 6, 7

Surgical resection of residual disease after imatinib response is potentially curative, with the National Comprehensive Cancer Network and other organizations suggesting that this approach can convert initially unresectable tumors to resectable ones 6

Treatment with imatinib should continue until disease progression, unacceptable toxicity, or surgical resection renders the patient disease-free, as generally recommended for targeted therapies in oncology 1, 2, 4
The safety profile of imatinib includes adverse events in at least 73.5% of patients, but severe adverse events in only 15.1%, as reported in various clinical trials and guidelines 1, 2, 4